查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1863643

全球吸入式一氧化氮市場：按系統、類型、組件、應用、最終用戶和地區劃分－市場規模、行業趨勢、機會分析和預測（2025-2033 年）

Global Inhaled Nitric Oxide Market: By System, Type, Component, Application, End Users, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 391 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

吸入式一氧化氮 (iNO) 市場正經歷顯著成長，預計到 2024 年將達到約 2.6617 億美元。預測顯示，到 2033 年，該市場規模將成長近一倍，達到約 4.7472 億美元。 2025 年至 2033 年的複合年增長率 (CAGR) 為 6.64%，反映了各個醫療領域對 iNO 療法的強勁且持續的需求。

推動市場強勁擴張的關鍵因素之一是對新生兒照護的日益重視。吸入式一氧化氮在治療新生兒呼吸系統併發症方面發揮著至關重要的作用。同時，便攜式吸入一氧化氮（iNO）系統的開發徹底改變了呼吸治療，顯著提高了治療的靈活性和可及性，尤其是在患者轉運和資源匱乏的環境下。這些便攜式設備增強了臨床醫生提供及時有效護理的能力，即使在傳統重症監護環境之外也是如此。

市場動態

吸入一氧化氮（iNO）市場競爭異常激烈，Mallinckrodt Pharmaceuticals、Linde plc 和 Air Liquide 等全球主要企業不斷透過創新產品開發、策略聯盟和擴大全球業務來爭奪市場領導地位。這種競爭推動了技術和服務的進步，確保醫療保健提供者能夠獲得可靠且有效的 iNO 療法。到 2024 年，這種競爭態勢將體現在對產能擴張的大量投資上，以滿足全球臨床對吸入一氧化氮日益增長的需求。

例如，林德集團（Linde plc）在其位於荷蘭的工廠新建了一座專門用於生產高純度一氧化氮鋼瓶的廠房，從而擴大了產能。此次擴建凸顯了林德集團致力於維護穩健可靠的供應鏈的戰略重點，這對於持續的患者護理至關重要。同樣，液化空氣集團（Air Liquide）也在美國德克薩斯州開設了一家新的生產工廠，以擴大其業務規模。

同時，總部位於波蘭的普萊克斯公司（Praxair）透過建立四個獨立的樞紐，優化了其包裝和分銷網絡，這些樞紐專門用於一氧化氮鋼瓶的加工和包裝。這項策略性措施最大限度地減少了從大量生產到交付的停機時間，從而創造了更順暢、更有效率的供應鏈。透過減少延誤，普萊克斯幫助醫療機構維持充足的吸入一氧化氮庫存，最終有助於改善患者的治療效果。

核心成長驅動因子

全球致力於改善新生兒護理的努力顯著推動了吸入一氧化氮 (iNO) 市場的擴張，這主要得益於人們對影響生命早期階段的呼吸系統併發症的日益關注。人們越來越認識到解決這些疾病至關重要，因此公共衛生組織積極推廣和補貼 iNO 解決方案，尤其是在資源匱乏、難以獲得先進呼吸護理的地區。這些努力旨在透過提高吸入一氧化氮療法的可及性和可負擔性來消除​​新生兒護理方面的不平等現象，而吸入一氧化氮療法對於治療危及生命的疾病（例如新生兒持續性肺動脈高壓 (PPHN)）至關重要。

新興機會

隨著便攜式吸入一氧化氮 (iNO) 系統在重症監護室 (ICU) 和手術室的廣泛應用，呼吸護理行業正在經歷一場重大變革，取代了傳統的鋼瓶式設備。 此變化源自於對更靈活且方便的給藥方式日益增長的需求，這些方式能夠更好地適應動態變化的病患照護。在過去九個月中，北美已有超過 50 家三級醫院將移動式吸入一氧化氮 (iNO) 裝置納入其治療方案。這些便攜式系統使臨床醫生能夠更輕鬆地進行一氧化氮治療，尤其是當患者需要在不同部門或機構間轉運時，從而確保持續、不間斷且有效的呼吸支持。

優化障礙

在各種醫療環境中保持吸入一氧化氮 (iNO) 劑量的一致性對於有效治療至關重要，但設備校準的複雜性帶來了巨大的挑戰。根據一份行業報告顯示，70 台在偏遠地區運行的行動醫療設備出現了校準偏差，導致一氧化氮濃度相差數 ppm。這種偏差會影響治療效果和病人安全，凸顯了精確校準以維持預期治療劑量的重要性。在行動醫療和資源有限的環境中，這些挑戰尤其突出，因為環境因素和設備限制會進一步增加校準的複雜性。

目錄

第一章：研究架構

  • 研究目標
  • 產品概述
  • 市場區隔

第二章：研究方法

  • 質性研究
    • 一手和二手資料來源
  • 量化研究
    • 一手和二手資料來源
  • 按地區劃分的原始調查受訪者
  • 研究假設
  • 市場規模估算
  • 資料三角驗證

第三章：摘要整理：全球吸入式一氧化氮市場

第四章：全球吸入式一氧化氮市場概論

  • 產業價值鏈分析
    • 原料供應商
    • 製造商
    • 經銷商
    • 終端用戶
  • 行業展望
    • 吸入一氧化氮的臨床應用
    • 吸入一氧化氮在 COVID-19 患者中的應用案例研究
    • 吸入一氧化氮治療新生兒呼吸衰竭 (NINOS)
    • 吸入一氧化氮治療 COVID-19 重症急性呼吸道症候群 (NOSARSCOVID)
    • 吸入一氧化氮的臨床試驗階段
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方協商談判力量
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場動態與趨勢
    • 成長推動因素
    • 阻礙因素
    • 挑戰
    • 主要趨勢
  • 新冠疫情對市場成長趨勢的影響評估
  • 市場成長與展望
    • 2020-2033年市場收入估計與預測
    • 2020-2033年市場估計與預測（基於銷售量）
    • 價格趨勢分析
  • 競爭格局概覽
    • 市場集中度
    • 公司市佔率分析（基於價值） 2024)
    • 競爭格局分析與基準測試

第五章 全球吸入式一氧化氮市場分析：依組件劃分

  • 主要發現
  • 市場規模及預測，2020-2033年
    • 硬體
    • 服務

第六章 全球吸入式一氧化氮市場分析：依系統劃分

  • 主要見解
  • 市場規模及預測，2020-2033年
    • 鋼瓶式系統
    • 電氣系統
    • 化學式系統

第七章 全球吸入式一氧化氮市場分析：依病患群體劃分類型

  • 主要發現
  • 市場規模及預測，2020-2033 年
    • 成人
    • 兒科

第八章 全球吸入一氧化氮市場分析：依應用領域劃分

  • 主要見解
  • 市場規模及預測，2020-2033 年
    • 肺動脈高壓
    • 結核病治療
    • 瘧疾治療
    • 慢性阻塞性肺病 (COPD)
    • 急性呼吸窘迫症候群 (ARDS)
    • 其他

第九章 全球吸入一氧化氮市場分析：依最終使用者劃分

  • 主要洞察
  • 市場規模及預測，2020-2033
    • 醫院
    • 診所
    • 門診中心

第十章：全球吸入一氧化氮市場區域分析

  • 主要發現
  • 市場規模及預測，2020-2033
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美

第十一章：北美吸入一氧化氮市場分析

第十二章：歐洲吸入一氧化氮市場分析

第十三章：亞太地區吸入一氧化氮市場分析

第十四章：中東與非洲吸入式一氧化氮市場分析

第十五章：南美洲吸入式一氧化氮市場分析

第十六章：美國吸入式一氧化氮市場分析

第十七章：英國吸入式一氧化氮市場分析

第十八章：德國吸入式一氧化氮市場分析

第十九章：法國吸入式一氧化氮市場分析

第二十章：義大利吸入式一氧化氮市場分析

第二十一章：西班牙吸入式一氧化氮市場分析

第22章：俄羅斯吸入式一氧化氮市場分析

第23章：波蘭吸入式一氧化氮市場分析

第24章：中國吸入式一氧化氮市場分析

第25章：日本吸入式一氧化氮市場分析

第26章 企業簡介

  • Air Liquide Healthcare
  • Bellerophon Therapeutics
  • Beyond Air
  • Circassia Pharmaceuticals
  • Getinge
  • International Biomedical
  • LINDE
  • Mallinckrodt Pharmaceuticals
  • Praxair(NoxBox)
  • SLE
  • Vero Biotech
  • Other major players
簡介目錄
Product Code: AA0423426

The inhaled nitric oxide (iNO) market is experiencing substantial growth, with its valuation reaching approximately US$ 266.17 million in 2024. Projections indicate that this market will nearly double by 2033, reaching an estimated value of US$ 474.72 million. This growth corresponds to a compound annual growth rate (CAGR) of 6.64% between 2025 and 2033, reflecting strong and sustained demand for iNO therapies across various healthcare sectors.

One of the primary drivers behind the market's robust expansion is the increasing focus on neonatal care, where inhaled nitric oxide plays a critical role in treating respiratory complications in newborns. Alongside this, the development of portable iNO systems has revolutionized respiratory therapy by offering greater flexibility and accessibility, particularly during patient transfers and in resource-limited settings. These portable devices enhance the ability of clinicians to deliver timely and effective care outside traditional intensive care environments.

Noteworthy Market Developments

The inhaled nitric oxide (iNO) market is characterized by a highly competitive landscape, dominated by key global players, such as Mallinckrodt Pharmaceuticals, Linde plc, and Air Liquide. These companies continuously vie for market leadership through innovative product development, strategic partnerships, and efforts to broaden their global presence. Their competition drives advancements in technology and service, ensuring that healthcare providers have access to reliable and effective iNO therapies. In 2024, this competitive spirit is reflected in significant investments to increase production capacity, aiming to meet the growing and steady demand for inhaled nitric oxide in clinical settings worldwide.

For instance, Linde plc enhanced its production capabilities by activating a specialized wing at its facility in the Netherlands dedicated exclusively to manufacturing high-purity nitric oxide canisters. This expansion underscores Linde's strategic focus on maintaining robust and dependable supply chains, which are critical for continuous patient care. Similarly, Air Liquide has expanded its operations in the United States by commissioning a new production site in Texas.

Meanwhile, Praxair in Poland has optimized its packaging and distribution network by dedicating four separate hubs to the processing and packaging of nitric oxide cylinders. This strategic move minimizes downtime between batch production and delivery, allowing for a smoother and more efficient supply chain. By reducing delays, Praxair helps ensure that healthcare facilities can maintain adequate inventories of inhaled nitric oxide, ultimately supporting better patient outcomes.

Core Growth Drivers

Efforts to enhance neonatal care on a global scale are significantly driving the expansion of the inhaled nitric oxide (iNO) market by bringing increased attention to respiratory complications that affect the earliest stages of life. The growing recognition of the critical need to address these conditions has motivated public health organizations to actively promote and subsidize iNO solutions, especially in resource-limited areas where access to advanced respiratory therapies remains a challenge. These initiatives aim to bridge gaps in neonatal care by improving the availability and affordability of inhaled nitric oxide treatments, which are essential for managing life-threatening conditions such as persistent pulmonary hypertension of the newborn (PPHN).

Emerging Opportunity Trends

A significant transformation is underway in respiratory care with the increasing adoption of portable inhaled nitric oxide (iNO) systems, which are progressively replacing traditional cylinder-based setups in intensive care units (ICUs) and surgical theaters. This shift is driven by the growing demand for more flexible and convenient delivery methods that can better accommodate the dynamic nature of patient care. Over the past nine months, more than 50 tertiary care hospitals across North America have integrated mobile iNO units into their treatment protocols. These portable systems allow clinicians to administer nitric oxide therapy with greater ease, especially during patient transfers between departments or facilities, ensuring continuous and effective respiratory support without interruption.

Barriers to Optimization

Device calibration complexities are posing significant challenges to achieving consistent dosing of inhaled nitric oxide (iNO) across various care settings, which is crucial for effective therapeutic administration. Industry reports reveal that 70 mobile healthcare units operating in remote regions have encountered calibration discrepancies, resulting in variations in iNO concentration by several parts per million. Such fluctuations can compromise treatment efficacy and patient safety, highlighting the critical need for precise calibration to maintain the intended therapeutic dose. These challenges are particularly pronounced in mobile or resource-limited settings, where environmental factors and equipment constraints may further complicate calibration efforts.

Detailed Market Segmentation

By System, cylinder-based systems have emerged as the dominant technology in the inhaled nitric oxide market, commanding a revenue share exceeding 53.1%. This leadership position is largely due to their well-established reliability and broad compatibility with various ventilator models used in critical care settings. These systems have become the preferred choice for healthcare providers because they consistently deliver precise and controlled doses of nitric oxide, which is essential for managing severe respiratory conditions. Their robust design and ease of integration with existing respiratory equipment ensure that they remain a trusted solution in intensive care units worldwide.

By Type, in 2024, the pediatric segment of the inhaled nitric oxide market captured a dominant share of over 77.5%, due to the therapy's critical importance in treating newborns with respiratory complications. This strong market presence is largely driven by the proven efficacy of inhaled nitric oxide in managing persistent pulmonary hypertension of the newborn (PPHN) and respiratory failure, conditions that require immediate and effective intervention to prevent long-term damage or mortality. For many neonates facing hypoxic respiratory challenges, inhaled nitric oxide provides a lifesaving alternative to more invasive procedures, helping to improve oxygenation and reduce the risk of complications associated with mechanical ventilation or surgery.

By Component, Acute Respiratory Distress Syndrome (ARDS) continues to be the leading component driving the inhaled nitric oxide market, holding over 59% of the market share. The widespread use of inhaled nitric oxide for ARDS is mainly due to its proven ability to enhance oxygenation and reduce pulmonary hypertension, both of which are critical factors in managing this severe respiratory condition. ARDS patients often suffer from severe hypoxemia, a dangerously low level of oxygen in the blood, and inhaled nitric oxide serves as an effective adjunct therapy to improve their respiratory function and overall outcomes.

By End Users, hospitals remain the predominant end users in the inhaled nitric oxide market, commanding a substantial market share of over 85.59%. This dominance is clearly reflected in the heightened procurement and utilization of nitric oxide therapies across some of the world's leading medical institutions. For instance, the Mayo Clinic has reported administering more than 4,500 nitric oxide treatments within the current year, underscoring the critical role this therapy plays in managing severe respiratory and critical care cases. The widespread acceptance of inhaled nitric oxide in hospital settings highlights its importance as a lifesaving intervention for patients with complex respiratory conditions.

Segment Breakdown

  • By System
  • Cylinder-Based System
  • Electric System
  • Chemical-Based System

By Type

  • Adults
  • Pediatrics

By Components

  • Hardware
  • Mechanical Ventilator
  • Flow Sensor
  • Respiratory Circuits Connectors
  • Nitric Oxide Container
  • Nitric Oxide Analyzer
  • Inlet & Outlet Pipe
  • Digital Monitor
  • Services
  • Managed Services
  • Professional Services
  • Consulting
  • Support & Maintenance

By Applications

  • Pulmonary Hypertension
  • Tuberculosis Treatment
  • Malaria Treatment
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Acute Respiratory Distress Syndrome (ARDS)
  • Others

By End User

  • Hospitals
  • Clinics
  • Ambulatory Centers

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • Europe holds a commanding position in the inhaled nitric oxide (iNO) market, capturing 41.3% of the global market share. This dominance is largely attributed to the region's sophisticated healthcare infrastructure, well-established clinical research networks, and extensive experience in managing complex respiratory conditions. These factors collectively enable Europe to lead in the adoption and utilization of iNO therapies. The region's commitment to advancing patient care is evident through the high volume of iNO-based interventions carried out in neonatal wards.
  • Germany stands out as the leader within Europe, performing close to 4,000 neonatal iNO procedures monthly, indicating its advanced neonatal care capabilities. The United Kingdom follows, with nearly 900 specialized iNO generators deployed across National Health Service hospitals, ensuring broad access to this critical therapy. France also contributes significantly, with cardiology departments conducting around 2,500 nitric oxide-assisted procedures during the first half of 2023, highlighting the treatment's importance beyond neonatal care into cardiovascular applications.

Leading Market Participants

  • Air Liquide Healthcare
  • Bellerophon Therapeutics
  • Beyond Air
  • Circassia Pharmaceuticals
  • Getinge
  • International Biomedical
  • LINDE
  • Mallinckrodt Pharmaceuticals
  • Praxair (NoxBox)
  • SLE
  • Vero Biotech
  • Other major players

Table of Content

Chapter 1. Research Framework

  • 1.1 Research Objective
  • 1.2 Product Overview
  • 1.3 Market Segmentation

Chapter 2. Research Methodology

  • 2.1 Qualitative Research
    • 2.1.1 Primary & Secondary Sources
  • 2.2 Quantitative Research
    • 2.2.1 Primary & Secondary Sources
  • 2.3 Breakdown of Primary Research Respondents, By Region
  • 2.4 Assumption for the Study
  • 2.5 Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Inhaled Nitric Oxide Market

Chapter 4. Global Inhaled Nitric Oxide Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Raw Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Clinical Applications of Inhaled Nitric Oxide
    • 4.2.2. Case study on Use of Inhaled Nitric Oxide on COVID-19 Patients
    • 4.2.3. Inhaled Nitric Oxide Study for Respiratory Failure in Newborns (NINOS)
    • 4.2.4. Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 (NOSARSCOVID)
    • 4.2.5. Clinical Trial Phases of Inhaled Nitric Oxide
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
    • 4.7.2. Market Volume Estimates and Forecast (Units), 2020-2033
    • 4.7.3. Price Trend Analysis
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping & Benchmarking

Chapter 5. Global Inhaled Nitric Oxide Market Analysis, By Component

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 5.2.1. Hardware
      • 5.2.1.1. Mechanical Ventilator
      • 5.2.1.2. Flow Sensor
      • 5.2.1.3. Respiratory Circuits Connectors
      • 5.2.1.4. Nitric Oxide Container
      • 5.2.1.5. Nitric Oxide Analyzer
      • 5.2.1.6. Inlet & Outlet Pipe
      • 5.2.1.7. Digital Monitor
    • 5.2.2. Services
      • 5.2.2.1. Managed Services
      • 5.2.2.2. Professional Services
      • 5.2.2.3. Consulting
      • 5.2.2.4. Support & Maintenance

Chapter 6. Global Inhaled Nitric Oxide Market Analysis, By System

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 6.2.1. Cylinder Based System
    • 6.2.2. Electric System
    • 6.2.3. Chemical Based System

Chapter 7. Global Inhaled Nitric Oxide Market Analysis, By Patient Type

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 7.2.1. Adults
    • 7.2.2. Pediatrics

Chapter 8. Global Inhaled Nitric Oxide Market Analysis, By Application

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 8.2.1. Pulmonary Hypertension
    • 8.2.2. Tuberculosis Treatment
    • 8.2.3. Malaria Treatment
    • 8.2.4. Chronic Obstructive Pulmonary Applications (COPD)
    • 8.2.5. Acute Respiratory Distress Syndrome (ARDS)
    • 8.2.6. Others

Chapter 9. Global Inhaled Nitric Oxide Market Analysis, By End User

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 9.2.1. Hospitals
    • 9.2.2. Clinics
    • 9.2.3. Ambulatory Centers

Chapter 10. Global Inhaled Nitric Oxide Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Inhaled Nitric Oxide Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 11.2.1. By Component
    • 11.2.2. By System
    • 11.2.3. By Patient Type
    • 11.2.4. By Application
    • 11.2.5. By End User
    • 11.2.6. By Country

Chapter 12. Europe Inhaled Nitric Oxide Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 12.2.1. By Component
    • 12.2.2. By System
    • 12.2.3. By Patient Type
    • 12.2.4. By Application
    • 12.2.5. By End User
    • 12.2.6. By Country

Chapter 13. Asia Pacific Inhaled Nitric Oxide Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 13.2.1. By Component
    • 13.2.2. By System
    • 13.2.3. By Patient Type
    • 13.2.4. By Application
    • 13.2.5. By End User
    • 13.2.6. By Country

Chapter 14. Middle East & Africa Inhaled Nitric Oxide Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 14.2.1. By Component
    • 14.2.2. By System
    • 14.2.3. By Patient Type
    • 14.2.4. By Application
    • 14.2.5. By End User
    • 14.2.6. By Country

Chapter 15. South America Inhaled Nitric Oxide Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 15.2.1. By Component
    • 15.2.2. By System
    • 15.2.3. By Patient Type
    • 15.2.4. By Application
    • 15.2.5. By End User
    • 15.2.6. By Country

Chapter 16. US Inhaled Nitric Oxide Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 16.2.1. By Component
    • 16.2.2. By System
    • 16.2.3. By Patient Type
    • 16.2.4. By Application
    • 16.2.5. By End User

Chapter 17. UK Inhaled Nitric Oxide Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 17.2.1. By Component
    • 17.2.2. By System
    • 17.2.3. By Patient Type
    • 17.2.4. By Application
    • 17.2.5. By End User

Chapter 18. Germany Inhaled Nitric Oxide Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 18.2.1. By Component
    • 18.2.2. By System
    • 18.2.3. By Patient Type
    • 18.2.4. By Application
    • 18.2.5. By End User

Chapter 19. France Inhaled Nitric Oxide Market Analysis

  • 19.1. Key Insights
  • 19.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 19.2.1. By Component
    • 19.2.2. By System
    • 19.2.3. By Patient Type
    • 19.2.4. By Application
    • 19.2.5. By End User

Chapter 20. Italy Inhaled Nitric Oxide Market Analysis

  • 20.1. Key Insights
  • 20.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 20.2.1. By Component
    • 20.2.2. By System
    • 20.2.3. By Patient Type
    • 20.2.4. By Application
    • 20.2.5. By End User

Chapter 21. Spain Inhaled Nitric Oxide Market Analysis

  • 21.1. Key Insights
  • 21.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 21.2.1. By Component
    • 21.2.2. By System
    • 21.2.3. By Patient Type
    • 21.2.4. By Application
    • 21.2.5. By End User

Chapter 22. Russia Inhaled Nitric Oxide Market Analysis

  • 22.1. Key Insights
  • 22.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 22.2.1. By Component
    • 22.2.2. By System
    • 22.2.3. By Patient Type
    • 22.2.4. By Application
    • 22.2.5. By End User

Chapter 23. Poland Inhaled Nitric Oxide Market Analysis

  • 23.1. Key Insights
  • 23.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 23.2.1. By Component
    • 23.2.2. By System
    • 23.2.3. By Patient Type
    • 23.2.4. By Application
    • 23.2.5. By End User

Chapter 24. China Inhaled Nitric Oxide Market Analysis

  • 24.1. Key Insights
  • 24.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 24.2.1. By Component
    • 24.2.2. By System
    • 24.2.3. By Patient Type
    • 24.2.4. By Application
    • 24.2.5. By End User

Chapter 25. Japan Inhaled Nitric Oxide Market Analysis

  • 25.1. Key Insights
  • 25.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 25.2.1. By Component
    • 25.2.2. By System
    • 25.2.3. By Patient Type
    • 25.2.4. By Application
    • 25.2.5. By End User

Chapter 26. Company Profile (Company Overview, Financial Matrix, Key Type landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 26.1. Air Liquide Healthcare
  • 26.2. Bellerophon Therapeutics
  • 26.3. Beyond Air
  • 26.4. Circassia Pharmaceuticals
  • 26.5. Getinge
  • 26.6. International Biomedical
  • 26.7. LINDE
  • 26.8. Mallinckrodt Pharmaceuticals
  • 26.9. Praxair (NoxBox)
  • 26.10. SLE
  • 26.11. Vero Biotech
  • 26.12. Other major players